Institutional Knowledge Map (KMap)
Map
Services
How To Use
About
Toggle theme
Loading...
Menu
Janiel Cragun
Associate Professor, Obstetrics and Gynecology - (Clinical Scholar Track)
Obstetrics and Gynecology
Map Page
Research Area
ovarian cancer,
chemotherapy,
cancer,
clinical trial,
rucaparib,
clinical trials,
endometrial cancer,
precision medicine,
case report,
cancer genetics
Grants
(8)
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tu
Active
·
2023
·
$0 / $560.9K
·
External
Co-Investigator (COI)
ovarian cancer,
combination therapy,
platinum-resistant,
peritoneal cancer,
fallopian-tube cancer
Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in Folate
Active
·
2023
·
$0 / $419.4K
·
External
Co-Investigator (COI)
chemotherapy,
antibody-drug conjugate,
ovarian cancer,
clinical trial,
folate receptor
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women
Active
·
2023
·
$0 / $270.2K
·
External
Co-Investigator (COI)
clinical trials,
cancer treatment,
immunotherapy,
chemotherapy,
women's health
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platnum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive
2023
·
$0 / $217.6K
·
External
Co-Investigator (COI)
cancer therapy,
clinical trial,
pharmacology,
immunotherapy,
drug development
A Phase 1/2 Dose Escalation and Dose Expansion Study of ZNc3 in Combination with Niraparib in Subjects with Platinum Resistant Ovarian Cancer
2023
·
$0 / $18.4K
·
External
Co-Investigator (COI)
ovarian cancer,
combination therapy,
dose escalation,
dose expansion,
platinum-resistant
Page 1 of 2
Previous page
Next page
Publications
(38)
Recent
Antiandrogen Flutamide-Induced Restoration of miR-449 Expression Mitigates Molecular Markers Associated with Ovarian Cancer Risk
2024
ovarian cancer,
mir-449,
antiandrogen,
molecular markers,
flutamide
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
2022
ovarian cancer treatment,
chemotherapy efficacy,
platinum-resistant cancer,
adavosertib therapy
Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without or Mutations
2019
chemotherapy,
hypersensitivity,
ovarian cancer,
genetic mutations,
peritoneal cancer
The utility of patient reported data in a gynecologic oncology clinic
2018
patient-reported outcomes,
gynecologic oncology,
clinical utility,
patient data,
healthcare outcomes
An Interdisciplinary program to prevent postoperative pneumonia: An Evidenced-Based Project.
2018
interdisciplinary program,
postoperative pneumonia,
evidenced-based project,
prevention,
healthcare
Incidence of Hypersensitivity Reactions to Carboplatin in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer with or without BRCA1 or BRCA2 Mutations
2018
drug hypersensitivity,
cancer treatment,
genetic mutations,
ovarian cancer,
brca mutations
Simple Patient Care Instructions Translate Best: Safety Guidelines for Physician Use of Google Translate
2017
patient care,
language translation,
physician guidelines,
safety,
google translate
Assessment of the Role of Intraoperative Frozen Section in Guiding Surgical Staging for Endometrial Cancer
2016
cancer,
surgery,
pathology,
endometrial,
diagnostic
Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deesequencing of circulating tumor DNA ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial abstract)
2016
cancer,
dna sequencing,
precision medicine,
clinical trials,
drug response
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma ARIEL2 Part 1) an international, multicentre, open-label, phase 2 trial
2016
ovarian cancer,
platinum-sensitive,
clinical trial,
rucaparib,
drug treatment
Collaborations
(10)
Setsuko Chambers
Mutual work: 6 Proposals﹒5 Grants﹒3 Publications
Collaboration Details
Guang Yao
Mutual work: 1 Publication
Collaboration Details
Hina Arif Tiwari
Mutual work: 2 Publications
Collaboration Details
Mitzi Miranda
Mutual work: 5 Grants﹒6 Proposals
Collaboration Details
Carolyn Lane
Mutual work: 1 Grant﹒1 Proposal
Collaboration Details
Page 1 of 2
Previous page
Next page
9+ Collaborators
$358.4K / $1.8M Funding
7+ Grants
30+ Publications